Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan + 5-FU/FA vs 5-FU/FA in Stage III Colon Cancer
NCT00026273Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2001
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of irinotecan in colon cancer (2 arms), sponsored by Pfizer. Primary endpoint: Disease-Free Survival at 3 years. Started Jan 2001; status: completed.
02
Drugs
irinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00026273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026273.